Medullary thyroid cancer prevention

Revision as of 09:48, 16 November 2015 by Ammu Susheela (talk | contribs)
Jump to navigation Jump to search

Medullary thyroid cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Medullary thyroid cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

CT

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Medullary thyroid cancer prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Medullary thyroid cancer prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Medullary thyroid cancer prevention

CDC on Medullary thyroid cancer prevention

Medullary thyroid cancer prevention in the news

Blogs on Medullary thyroid cancer prevention

Directions to Hospitals Treating Medullary thyroid cancer

Risk calculators and risk factors for Medullary thyroid cancer prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

According to the American Society of Clinical Oncology, surveillance for medullary thyroid cancer by annual measurement of serum calcitonin, serum calcium, serum parathyroid hormone, and catacholamines is recommended postsurgically to monitor for recurrence and complications for medullary thyroid cancer.

Prevention

Surveillance of medullary thyroid cancer
Serum calcium level annually for people diagnosed with multiple endocrine neoplasia type 2A
Recurrent or residual medullary thyroid cancer post thyroidectomy is detected by measurement of serum calcitonin annually
Adapted from Marquard J, Eng C. Multiple Endocrine Neoplasia Type 2. 1999 Sep 27 [Updated 2015 Jun 25]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1257/[1]











References

  1. Jessica Marquard & Charis Eng (1993). "Multiple Endocrine Neoplasia Type 2". PMID 020301434.

Template:WikiDoc Sources